• Calliditas virtual R&D Day on
    January 20, 2021

  • Key Opinion Leader (KOL) Perspectives webinar

    March 10, 2021 at 10:00am Eastern Time.

  • Calliditas Presentation at the Jefferies Virtual Healthcare Conference


Calliditas is focused on the development and commercialization of its lead product candidate Nefecon.


A potential treatment for patients with IgA nephropathy at risk of developing ESRD.

Behind the Mystery: IgA Nephropathy

The Balancing Act, Lifetime TV’s morning program, aired a half-hour segment on IgA Nephropathy in the ‘Behind the Mystery’ program. An IgA patient and Leicester University’s Professor Jonathan Barratt discussed the disease and the challenges patients face due to lack of specifically developed treatments.

Share price Sweden

Share price US

Interim Report Q1 2021

On May 18, 2021, at 07:00 CEST, Calliditas Therapeutics published its interim report for the first quarter 2021. A conference call will be held to present and discuss the results, at 2.30 pm CEST.